Patent: 7,183,254
✉ Email this page to a colleague
Summary for Patent: 7,183,254
| Title: | Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment |
| Abstract: | Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipoatrophy. Leptin is effective against conditions of lipoatrophy for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including subcutaneously and using gene therapy methods. Methods of the present invention contemplate administration of leptin, leptin analogs, and leptin derivatives to patients having a leptin level of approximately 4 ng/ml or less before treatment. |
| Inventor(s): | Alexander M. DePaoli, Simeon I. Taylor, Elif A. Oral, Abhimanyu Garg |
| Assignee: | Amgen Inc , University of Texas System , US Department of Health and Human Services |
| Application Number: | US10/623,189 |
| Patent Claims: | see list of patent claims |
Details for Patent 7,183,254
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Chiesi Farmaceutici S.p.a. | MYALEPT | metreleptin | For Injection | 125390 | 24-Feb-14 | 7,183,254 | 2023-07-18 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
